Nevirapine is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

Pediatrics Central

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of HIV infection in combination with other antiretroviral agents.
  • Due to increased risk of hepatitis, avoid starting NVP in women with pre-treatment CD4 >250 and men with CD4 >400.

NON-FDA APPROVED USES

  • Single dose at time of delivery to prevent perinatal transmission (widely used in developing countries, but risk of NNRTI resistance; combination therapy preferred when available). Risk of hepatitis for women with CD4 >250 does not apply to single dose NVP.

-- To view the remaining sections of this topic, please or purchase a subscription --

Last updated: June 27, 2014

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Nevirapine ID - 540383 A1 - Bartlett,John,M.D. AU - Hsu,Alice,Pharm.D. AU - Pham,Paul,Pharm.D. Y1 - 2014/06/27/ BT - Johns Hopkins ABX Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540383/all/Nevirapine PB - The Johns Hopkins University DB - Pediatrics Central DP - Unbound Medicine ER -